managing early & late relapse after first-line therapy for dlbcl
Published 1 year ago • 258 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:55
treatment options for dlbcl patients who relapse after car-t cell therapy
-
5:24
treatment strategies for patients with dlbcl who relapse after car-t therapy
-
1:56
the need for new treatment strategies for patients with dlbcl
-
2:03
novel treatment approaches for early-stage dlbcl
-
4:26
mrd assessment for surveillance post-treatment in dlbcl
-
1:55
exploring first-line car-t therapy for the treatment of dlbcl
-
1:04
bispecifics & car-t therapy in dlbcl: sequencing and selecting between these agents
-
3:35
outcomes of patients with dlbcl who relapse early following r-ice chemoimmunotherapy
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
3:34
effect of time to relapse on os in mcl following autohct
-
2:10
new algorithm for second-line dlbcl: the role of car-t therapy
-
2:38
emerging strategies for the management of relapsed aml
-
3:04
applying molecular understanding of dlbcl to management strategies
-
6:28
outcomes following first-line therapy in routine clinical practice in alcl
-
3:09
treatment strategies for chl patients after auto-hsct
-
2:40
asct in relapsed myeloma patients
-
3:21
safety management of car-t cell therapy in dlbcl
-
1:45
ham-ven as salvage treatment for r/r aml: results from the sal-relax trial